East Midlands Cancer Network Guidelines for the Investigation and Management of Adult Myelodysplastic Syndromes
|
|
- Eustace Bond
- 7 years ago
- Views:
Transcription
1 East Midlands Cancer Network Guidelines for the Investigation and Management of Adult Myelodysplastic Syndromes Written by: Dr Emma Das-Gupta and Dr Jane Parker 1. Scope of the Guideline Consultation Group: EMCN Haematology NSSG This guidance has been produced to support the following: a. The investigation of patients suspected of having a myelodysplastic syndrome b. the management of patients diagnosed with a myelodysplastic syndrome 2. Guideline Background These guidelines support the BCSH Guidelines for the Diagnosis and Therapy of Adult Myelodysplastic Syndromes 5. They also take into account newer therapies that have become available for the treatment of myelodysplastic syndromes since the publication of the BCSH guidelines. 3. Diagnostic Workup of Suspected Myelodysplastic Syndrome (MDS) 3.1 History should be taken including: a. Symptoms of anaemia, recurrent infections, bleeding/bruising b. Prior exposure to chemotherapy/radiation c. Prior chemical exposure, especially benzene d. Family history of MDS/Acute Myeloid Leukaemia 3.2 Physical Examination should include: a. Pallor/infection/bruising b. Splenomegaly c. Dysmorphic features (suggesting congenital bone marrow failure) d. Cutaneous lesions Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 1/14
2 3.3 Initial Blood Tests should take place as follows: a. Full blood count and blood film: o cytopenia(s) o Monocytosis, o red cell macrocytosis, o dysplastic features b) Reticulocyte count c) Ferritin d)β 2 Microglobulin e) LDH 3.4 Consider and Exclude other Causes of Dysplasia and Cytopenias B12 / folate deficiency Recent cytotoxic therapy Drug-induced cytopenias Chronic liver disease Excessive alcohol intake Hypothyroidism Exposure to heavy metals, e.g. lead, arsenic HIV infection Anaemia of chronic disorders (infection, inflammation, cancer) Autoimmune cytopenia Other hemopoietic stem cell disorders including acute myeloid leukaemia, myeloproliferative disorders, aplastic anaemia, paroxysmal nocturnal haemoglobinuria, LGL leukaemia and hairy cell leukaemia. 3.5 Additional Blood Tests to consider a. PNH clone in suspected hypoplastic MDS b. JAK2 analysis in RARS-T c. Fanconi screen if constitutional MDS considered possible 3.6 Bone Marrow Aspirate A good quality bone marrow aspirate is necessary to make a confident diagnosis of MDS and to provide important information regarding disease classification and prognosis. MGG / equivalent and iron stains should be undertaken. A bone marrow aspirate may not be necessary in elderly patients in whom a definitive diagnosis of MDS would not alter management or whose poor general health precludes active treatment. Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 2/14
3 3.7 Bone Marrow Trephine Bone marrow histology complements the morphological information obtained from a marrow aspirate and hence a trephine biopsy should be performed in all cases of suspected MDS where bone marrow examination is indicated. The trephine can provide information regarding marrow cellularity and fibrosis, aiding the identification of hypocellular MDS and overlap myelodysplastic/myeloproliferative syndromes. 3.8 Cytogenetic Analysis of Bone Marrow A chromosomal abnormality confirms the presence of a clonal disorder aiding the distinction between MDS and reactive causes of dysplasia. In addition it provides major prognostic value. Cytogenetic analysis should therefore be performed in all patients for whom bone marrow examination is indicated. FISH analysis may be helpful to clarify complex aberrations or to detect monosomy 5 or Immunophenotypic Analysis of Bone Marrow Immunophenotyping of bone marrow is recommended and can be useful in determining the percentage of marrow blasts, particularly when myeloid dysplasia makes morphological enumeration difficult. The marrow blast percentage is necessary for disease classification and prognostication Morphological Diagnostic Criteria for MDS Minimal diagnostic criteria are not clearly defined in MDS and the diagnosis of MDS is susceptible to inter-observer variation. Difficulties also arise because a variety of reactive disorders are associated with dysplastic morphology and mild dysplastic features are frequently seen in the marrow of healthy people with normal blood counts 2. In order to increase the reliability of diagnosing MDS, the following recommendations are made: a. Where possible at least 200 marrow cells and 20 megakaryocytes should be evaluated. b. For significant dysplasia, dysplastic features should be present in at least 10% of the nucleated cells in the lineage in consideration. c. The presence of pseudo-pelger neutrophils, ring sideroblasts, micromegakaryocytes and increased blasts correlate most strongly with the presence of clonal markers in MDS and show least interobserver variation. d. It is recommended that a diagnosis of MDS is not based on the presence of neutrophil hypogranularity alone, due to the fact that neutrophil granularity is critically dependent on optimal staining. For a full description of dysplastic features see WHO 2008, page 90 1 Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 3/14
4 If morphological diagnosis remains uncertain, it is recommended that the patient be monitored with repeat morphological assessment at appropriate intervals Hypocellular MDS versus Aplastic Anaemia The diagnosis of hypocellular MDS is of importance, as preliminary data suggest that the response to immunosuppressive therapy is higher than in cases of MDS with normo or hypercellular marrows 4. The diagnosis of myelodysplasia requires the presence of dysplastic features in megakaryocytes and/or myeloid cells or/ and excess of blasts. Erythroid dysplasia is found in aplastic anaemia and cannot be used alone to distinguish MDS from AA. The presence of an abnormal karyotype strongly favours the diagnosis of MDS, but cases of aplastic anaemia with an abnormal karyotype, without morphological features of MDS, and with a low risk of transformation to MDS or AML, have been described Idiopathic Cytopenia of Undetermined Significance (ICUS) Patients with maintained (>6 months) cytopenias of one or more myeloid lineages (erythroid, neutrophil and megakaryocytic), which do not meet the (minimal) criteria for MDS and cannot be explained by any other hematologic or non-hematologic disease may be considered as ICUS. In some patients, the type of cytopenia (e.g., transfusion-dependent macrocytic anemia) may point to the potential existence of an underlying MDS or an MDS pre-phase MDS Classification Patients with MDS are classified according to the WHO classification system 1 (Tables 1 and 2). Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 4/14
5 Table 1: WHO 2008 Classification of MDS Disease Blood Findings Bone Marrow Findings Refractory cytopenias with unilineage dysplasia (RCUD) Refractory anaemia (RA) Refractory neutropenia (RN) Refractory thrombocytopenia (RT) Unicytopenia or bicytopenia 1 No or rare blasts (<1%) Refractory anaemia with ring sideroblasts (RARS) Refractory cytopenia with multilineage dysplasia (RCMD) Refractory anaemia with excess blasts-1 (RAEB- 1) Refractory anaemia with excess blasts-2 (RAEB- 2) Myelodysplastic syndrome unclassified (MDS-U) Anemia No blasts Cytopenia(s) No or rare blasts (<1%) 2 No Auer rods <1x109/l monocytes Cytopenia(s) <5% blasts No Auer rods <1x109/l monocytes Cytopenia(s) 5-19% blasts Auer rods 3 <1x109/l Unilineage dysplasia; 10% of the cells of the affected lineage are dysplastic <5% blasts <15% of the erythroid precursors are ring sideroblasts Erythroid dysplasia only 15% of erythroid precursors are ring sideroblasts Dysplasia in 10% of cells in two or more myeloid lineages (neutrophil and/or erythroid precursors and/or megakaryocytes) <5% blasts No Auer rods 15% ring sideroblasts Unilineage or multilineage dysplasia 5-9% blasts 2 No Auer rods Unilineage or multilineage dysplasia 10-19% blasts Auer rods monocytes Cytopenias a. Dysplasia in less than 10% but 1% blasts 2 typical cytogenetic abnormality b. RCUD/RCMD with 1% blasts in peripheral blood c. RCUD with pancytopenia MDS associated with isolated del(5q) Anaemia Usually normal or increased platelet count No or rare blasts (<1%) Normal to increased megakaryocytes with hypolobated nuclei <5% blasts Isolated del(5q) cytogenetic abnormality No auer rods 1 Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U 2 If the marrow myeloblast percentage is <5% but there are 2-4% myeloblasts in the blood, the diagnostic classification is RAEB-1. If the marrow myeloblast percentage is <5% and there are 1% myeloblasts in the blood, the case should be classified as MDS-U. 3 Cases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be classified as RAEB-2 Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 5/14
6 Table 2 WHO 2008 classification of myelodysplastic/myeloproliferative neoplasms Disease Blood findings Bone marrow findings Chronic myelomonocytic leukaemia (CMML) (CMML-1; <5% blasts in PB, <10% in BM, CMML-2; 5% blasts in PB, 10% in BM) Atypical chronic myeloid leukaemia, BCR- ABL1 negative (acml) Juvenile myelomonocytic leukaemia (JMML) Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN) 1Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) (provisional entity)2 Peripheral blood monocytosis > 1x109/l No BCR/ABL-1 fusion gene <20% blasts Leukocytosis, neutrophilia Neutrophilic dysplasia Neutrophil precursors 10% of leukocytes Blasts <20% No BCR-ABL1 fusion gene No rearrangement of PDGFR or PDGFR Minimal basophilia Monocytes < 10% of leukocytes Peripheral blood monocytosis >1x109/l <20% blasts Usually WBC > 10x109/l Mixed MDS and MPN features No prior diagnosis of MDS or MPN No history of recent growth factor or cytotoxic therapy to explain MDS or MPN features No BCR-ABL1 fusion gene of rearrangements of PDGFR or PDGFR Persistent thrombocytosis >450x10 9 /L Anaemia BCR-ABL1 negative Cases with t(3;3)(q21;q26), inv(#)(q21q26) and isolated del(5q) are Dysplasia in one or more myeloid lineage 1 <20% blasts. Blasts include myeloblasts, monoblasts and promonocytes. No rearrangement of PDGFR or PDGFR Neutrophil dysplasia with or without dysplastic lineages <20% blasts <20% blasts Evidence of clonality Mixed MDS and MPN features <20% blasts Morphologic features of RARS; 15% of erythroid precursors are ring sideroblast Abnormal megakaryocytes similar to those observed in BCR-ABL1 negative MPN 50% JAK2 mutations in RARS-T with plt>600. excluded 1 I f myelodysplasia minimal or absent, CMML can still be diagnosed if the other requirements are met and there is an acquired clonal cytogenetic or molecular genetic abnormality. Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U 2 If the marrow myeloblast percentage is <5% but there are 2-4% myeloblasts in the blood, the diagnostic classification is RAEB-1. If the marrow myeloblast percentage is <5% and there are 1% myeloblasts in the blood, the case should be classified as MDS-U. 3 Cases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be classified as RAEB-2 Note: Therapy-associated MDS and MDS/MPN should classified in the category therapy-associated myeloid malignancies Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 6/14
7 3.14 MDS Prognosis Since its publication in 1997, the International Prognostic Scoring System (IPSS) has been an important tool for assessing the outcome of patients with untreated, primary adult MDS 8 (Tables 3 and 4). The Revised IPSS (IPSS-R) has recently described the relative importance of defined clinical factors with regards to prognosis by multivariate analysis of 7012 primary, untreated adult MDS patients 12 (Tables 5 a-c). The IPSS-R has 5 prognostic categories and has improved the prognostic ability to determine survival and AML evolution in untreated adult patients with primary MDS. This model should be the preferred scoring system for determining prognosis and appropriate treatment. The score can be calculated on the following webpage Table 3 IPSS for MDS Prognostic Variable Score Value BM Blasts (%) < Karyotype Good Intermediate Poor Cytopenias 0/1 2/3 Karyotype: Good: normal, -Y, del(5q), del(20q). Poor: complex ( 3 abnormalities) or chromosome 7 anomalies. Intermediate: other abnormalities. Cytopenias: Hemoglobin <10 g/dl, ANC <1.8 x 10 9 /l, platelets <100 x 10 9 /l. Table 4: IPSS Interpretation Risk group Score Median survival (years) Time to AML transformation (for 25% in years) Low risk INT INT High risk Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 7/14
8 Table 5a. IPSS-R Cytogenetic Prognostic Subgroups (Greenberg, et al 2012) 12 Very good -Y, del(11q) Good Normal, del(5q), del(12p), del(20q), double including del(5q) Intermediate del(7q), +8, +19, i(17q), any other single or double independent clones Poor -7, inv(3)/t(3q), double including - 7/del(7q), complex: 3 abnormalities Very Poor Complex: >3 abnormalities Table 5b. IPSS-R Prognostic Score Values (Greenberg, et al 2012) Prognostic variable Cytogenetics Very Good Good Intermediate Poor Very Poor BM blast % 2 >2-< >10 Haemoglobin 10 8-<10 <8 Platelets <50 <100 ANC 0.8 <0.8 Table 5c. IPSS-R Prognostic Risk Categories/Scores and Clinical Outcomes (Greenberg, et al 2012) RISK CATEGORY RISK SCORE SURVIVAL (median years) AML/25% (median years) Very Low NR Low > Intermediate > High > Very High > Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 8/14
9 Additional differentiating features were noted in the IPSS-R that are additive to the 5 major parameters for predicting survival but not for AML evolution. These features are performance status, serum ferritin, LDH, and possibly β 2 - microglobulin. Additional adverse features that may influence management decisions are heavy transfusion dependence and marrow fibrosis. 6. Management of Patients Diagnosed with a Myelodyspastic Syndrome 6.1. Pre-treatment Management All patients with a diagnosis of MDS must be discussed at an MDT Referral to a Haematology Specialist Nurse if available Written material to be provided according to local protocol, for example: o MDS UK Patient Support Group leaflet and news letter o LLR MDS booklet o Leukaemia CARE booklet o Leukaemia CARE contact card o Macmillan booklet o Macmillan contact card o Macmillan Cancerline contact number o NHS Choices Information Presrciption o Haematology Ward contact details? then divide sections into A. Supportive care B. low risk MDS, C. high risk MDS as in the BCSH guidelines 6.2 Supportive Care Anaemia Red Cell Transfusion The use of red cell transfusions should be considered in any patient with symptoms of anaemia. Blood transfusions should be administered according to local Trust transfusion policies Neutropenia Neutropenic sepsis should be managed as for patients undergoing chemotherapy according to the hospital antibiotic policy. There is no indication for routine antibiotic or antifungal prophylaxis. The use of GCSF may be considered in patients with recurrent infections who have low risk disease. Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 9/14
10 6.2.3 Thrombocytopenia Both the degree of thrombocytopenia and platelet dysfunction can contribute to bleeding problems. Routine prophylactic platelet transfusion may be of symptomatic value in individual patients but there is no evidence to support their routine use in stable thrombocytopenia (in patients not undergoing intensive chemotherapy), even with platelet counts less than 10x10 9 /l 5. In the absence of bleeding or fever, the threshold for platelet transfusion in symptomatic patients is 10 x 10 9 /L. Antifibrinolytics may be useful in some patients but caution should be taken in patients with ischaemic heart disease. 6.3 Low Risk MDS Low risk MDS is defined as patients who have an IPSS of Low or Intermediate-1, or an IPSS-R of Very Low or Low Iron Chelation Iron chelation should be considered principally in stable transfusiondependent patients with low/int-1 IPSS. The clinical relevance of iron overload in MDS is still not clear and the role of iron chelation therapy, in terms of patient suitability and specific benefit, has yet to be clearly defined in prospective clinical studies. Consensus guidelines and statements for the treatment of iron overload in patients with MDS have been published 73. The BCSH guidelines recommend treatment of iron overload in low IPSS risk patients when they have received approximately 25 units of blood (5g of iron) aiming to maintain serum ferritin levels below 1000μg/l 5. The EMCN has elected to use T2* MRI to guide the initiation of iron chelation in MDS according to the algorithm given in figure 1 Drugs for Iron Chelation First line: s/c Desferrioxamine, -consider home care provider. Refer to link: Application for new patient on Desferrioxamine inc MDS (word version) Second Line: Deferasirox may be considered in patients who are intolerant of desferrioxamine Annual eye and ear assessments should be carried out in patients taking these drugs. There is no evidence for benefit from IV desferrioxamine given at the same time as blood transfusion and this is not recommended. Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 10/14
11 Figure 1: Algorithm for the Initiation of Iron Chelation in MDS Consultant Haematologist Decision to Consider Chelation Life Expectancy >2 years IPSS low or int -1 >25 units RBC Transfused Ferritin 1500 MRI possible No Ferritin 3000 New Onset Endocrinopath y at any Stage T2* MRI of Heart and Liver No Liver Iron or Mild Liver Iron Overload (T2*>2.7ms) Moderate Liver Iron Overload (T2*2.7ms - 1.4ms) High Liver Iron Overload (T2* 1.4ms) and/or any Cardiac Iron Loading (T2* 20ms) Repeat MRI Annually Repeat MRI Six Monthly Start Chelation Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 11/14
12 6.3.2 Erythropoietin (EPO) and GCSF EPO ±GCSF can reduce transfusion requirements and potentially improve long term survival in selected patients 9,10. Patients with low or Int-1 MDS, who have a serum EPO level <500 and whose transfusion requirement is 2 units of blood per month should be considered for an eight week trial of EPO. For those who show no response, consider a further 8 week trial of EPO with GCSF. Consider combining EPO with GCSF from the outset in sideroblastic cases. The haemoglobin should not be allowed to rise above 12 g/dl Immunosuppressive Therapy Immunosuppression with ATG or cyclosporin can be beneficial in subgroups of MDS (mainly younger int-1 patients) 11. Immunosuppressive therapy with ATG (horse) can be considered for patients with low or Int-1 IPSS MDS below the age of 60 years, particularly those who have a hypoplastic bone marrow and a normal karyotype or trisomy 8. ATG should only be used in centres with experience of its use in aplastic anaemia q- Syndrome Lenalidomide is not currently licensed for use in this group of patients and applications for use would need to be made locally on an individual patient basis Stem Cell Transplantation Allogeneic HSCT is the only treatment modality with proven curative potential for MDS. Therefore all patients with newly diagnosed MDS should be discussed at an MDT and the role of allogeneic HSCT considered. 6.4 High Risk MDS Non-Intensive Treatment Patients >60 years with >10% blasts, who are not considered candidates for intensive chemotherapy, should be offered therapy within the LI1 nonintensive trial or consider AML18 if available. 5-Azacitidine (Vidaza) Azacitidine is a hypomethylating agent with efficacy in high grade MDS that has been shown to significantly increase overall survival compared to conventional care regimens (specifically, best supportive care, low dose cytarabine and intensive AML-type therapy) 6. Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 12/14
13 Azacitidine is approved by NICE as a treatment option for adults who are not eligible for haematopoietic stem cell transplantation and who have: Intermediate-2 and high-risk myelodysplastic syndromes according to the International Prognostic Scoring System (IPSS) or Chronic myelomonocytic leukaemia with 10 29% marrow blasts without myeloproliferative disorder or Acute myeloid leukaemia with 20 30% blasts and multilineage dysplasia, according to the World Health Organization classification and if the manufacturer provides azacitidine with the discount agreed as part of the patient access scheme. The recommendation in the East Midlands is that patients should be considered for entry into clinical trials such as LI1 or AML18 as initial treatment of their high grade MDS. Azacitidine is an alternative therapy that may be considered. Patients who are initially treated with azacitidine for high grade MDS and who then progress to AML may still be offered entry into LI1. Low dose ara C may also be offered to patients with >10% blasts including patients with CMML2. Hydroxycarbamide should be considered as cytoreductive therapy for patients with CMML associated with a high white cell count Intensive chemotherapy and transplantation Patients with >10% blasts in the marrow who are considered fit to tolerate intensive chemotherapy should be offered therapy within the AML18 or AML17 trials. Non-trial patients fit for intensive chemotherapy should receive chemotherapy as per the AML guidelines. Outside of a trial setting, chemotherapy is usually limited to 2-3 courses due to the risk of prolonged cytopenias and poor haemopoietic regeneration with more courses. Indications for allogeneic transplantation in MDS are published by the BSBMT: For patients in AML 17, which uses a different risk score, patients defined as high risk are eligible for sibling or unrelated donor transplantation. Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 13/14
14 Reference List 1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth ed Bain BJ. The bone marrow aspirate of healthy subjects. Br J Haematol. 1996;94: Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83: Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94: Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120: Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higherrisk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10: Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res. 2007;31 Suppl 3:S10-S Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: Hellstrom-Lindberg E, Negrin R, Stein R et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99: Jadersten M, Malcovati L, Dybedal I et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26: Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy. Journal of Clinical Oncology. 2008;26: Greenberg, P.L., Tuechler, H., Schanz, J., et al Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, Written By: Dr Emma Das-Gupta Dr J Parker Authorised by: Haem NSSG Page Number: 14/14
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
More informationAcute Myelogenous Leukemia Pre-HSCT Data
Instructions for Acute Myelogenous Leukemia Pre-HSCT Data (Form 2010) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the AML Pre-HSCT Data Form. E-mail
More informationMyelodysplasia. Dr John Barry
Myelodysplasia Dr John Barry Myelodysplasia Group of heterogenouus bone marrow disorders that are due to a defect in stem cells. Increasing bone marrow failure leading to quan>ta>ve and qualita>ve abnormali>es
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationGuidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Nordic MDS Group
Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Nordic MDS Group Issue 7 6 th update, 1 st of February 2014 1 WRITING COMMITTEE... 4 CONTACT
More informationMULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
More informationAcute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
More informationOncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
More informationBasics of AML. Acute myeloid leukemia and related myeloid neoplasms: WHO 2008 brings us closer to understanding clinical behavior
Acute myeloid leukemia and related myeloid neoplasms: WHO 2008 brings us closer to understanding clinical behavior No conflicts of interest to disclose Steven Devine, MD The Ohio State University Common
More informationMyelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma
Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma Hodgkin Lymphoma Overview Case Pathophysiology Diagnosis
More informationNGS e malattie mieloproliferative
NGS e malattie mieloproliferative Matteo G Della Porta Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia Medical School, Pavia, Italy matteo@haematologica.org
More informationUnderstanding Myelodysplastic Syndromes: A Patient Handbook
UNITED STATES Understanding Myelodysplastic Syndromes: A Patient Handbook Sixth Edition the myelodysplastic syndromes foundation, inc. Published by The Myelodysplastic Syndromes Foundation, Inc. Understanding
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationPage 1. Current Concepts: Etiology, Clinical Manifestations, and Treatment. Gary Schiller, MD
Treating Higher-Risk Myelodysplasia Current Concepts: Etiology, Clinical Manifestations, and Treatment Gary Schiller, MD Presentations in Two Patients 86 y.o. male with a 6-y hx of macrocytic anemia referred
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationSynopsis of Causation. Chronic Myeloid Leukaemia
Ministry of Defence Synopsis of Causation Chronic Myeloid Leukaemia Author: Dr M A Vickers, University of Aberdeen, Aberdeen Validator: Professor John Goldman, Hammersmith Hospital, London September 2008
More informationPoročilo EHA 2012. Simon Bitežnik
Poročilo EHA 212 Simon Bitežnik 1 Burden of chronic anaemia in patients with MDS Anaemia is a major clinical problem in patients with MDS ~8% patients are anaemic at diagnosis 1 In patients with MDS, anaemia
More informationControversies in the management of patients with PMF 0/1
State of the art treatments of patients with MPNs Turracher Höhe 2010 Controversies in the management of patients with PMF 0/1 Heinz Gisslinger Medical University of Vienna Divison for Hematology, Vienna
More informationWhat Does My Bone Marrow Do?
What Does My Bone Marrow Do? the myelodysplastic syndromes foundation, inc. Illustrations by Kirk Moldoff Published by The Myelodysplastic Syndromes Foundation, Inc. First Edition, 2009. 2012. Table of
More informationPathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
More informationCytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not
More informationEvidence Review Group s Report
Evidence Review Group s Report Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Produced by Authors West Midlands Health Technology
More informationCASE 2. Seven week old female infant presents with hepatosplenomegaly l and WBC 31.0k/mm 3, Hgb 9.2 g/dl, Plt 110k/mm 3 with 60% blasts
CASE 2 Seven week old female infant presents with hepatosplenomegaly l and WBC 31.0k/mm 3, Hgb 9.2 g/dl, Plt 110k/mm 3 with 60% blasts A bone marrow biopsy and aspirate were performed (photos provided).
More informationUniversity of California San Diego, January 31, 2015 Part 1 Page 1 of 22
University of California San Diego, January 31, 2015 Part 1 Page 1 of 22 Sandy Kurtin, RN, MS, AOCN, ANP-C Rafael Bejar, MD, PhD Dr. Rafael Bejar: Some of the questions you have will be questions that
More informationHematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
More informationThe Clinical Management of Chronic Myelomonocytic Leukemia
The Clinical Management of Chronic Myelomonocytic Leukemia Eric Padron, MD, Rami Komrokji, and Alan F. List, MD Dr Padron is an assistant member, Dr Komrokji is an associate member, and Dr List is a senior
More informationWhat is chronic lymphocytic leukaemia?
Revised October 2011 What is chronic lymphocytic leukaemia? The diagnosis of a blood cancer can be a devastating event for patients, families and friends. It is therefore vital for everyone to have access
More informationCLINICAL AND MOLECULAR EFFECTS OF AZACITIDINE IN THE MYELODYSPLASTIC SYNDROMES
Institutionen för medicin, Huddinge, H7 Karolinska Institutet, Stockholm, Sweden CLINICAL AND MOLECULAR EFFECTS OF AZACITIDINE IN THE MYELODYSPLASTIC SYNDROMES Magnus Tobiasson Stockholm 2015 All previously
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationNEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010
NEW YORK STATE CYTOHEMATOLOGY PROFICIENCY TESTING PROGRAM Glass Slide Critique ~ November 2010 Slide 081 Available data: 72 year-old female Diagnosis: MDS to AML WBC 51.0 x 10 9 /L RBC 3.39 x 10 12 /L
More informationGuideline for the Management of Acute Lymphoblastic Leukaemia (ALL) in Adults
Guideline for the Management of Acute Lymphoblastic Leukaemia (ALL) in Adults Version History Version Date Summary of Change/Process 1.0 The UKALL trial protocol was approved as version 1. 1.1 22.07.10
More informationGuidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)
Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at
More informationSubtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
More informationUnderstanding Myelodysplastic Syndromes: A Patient Handbook
Understanding Myelodysplastic Syndromes: A Patient Handbook Peter A. Kouides, MD John M. Bennett, MD Peter Kouides is Associate Professor of Medicine, University of Rochester School of Medicine and Dentistry,
More informationDEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
More informationBone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate
Original Article Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate Joshi S, Sunita P, Deshmukh C, Gujral S, Amre P, Nair CN Department of Pathology,
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationCollect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.
Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationAcute myeloid leukaemia (AML) in children
1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of
More informationLenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality
in collaboration with: Lenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality Produced by Authors Correspondence to Kleijnen Systematic Reviews
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationTreatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
More informationAr Mino changes including adjustment of therapy algorithms
cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationInteresting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
More informationCareers in Haematology
Careers in Haematology A Guide for Medical Students and Junior Doctors Haematology is the medical speciality concerned with blood disorders. Your non-medical friends however will always think that you
More informationMDetails about molecular abnormalities; the SEER incidence data; link to PNH; new WPSS score, additional
yelodysplastic Syndromes (MDS) Drs. Rena Buckstein & Richard Wells Updated May 2008* Updates: MDetails about molecular abnormalities; the SEER incidence data; link to PNH; new WPSS score, additional baseline
More informationThe CML Guide Information for Patients and Caregivers
The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President
More informationRDW-- Interpreting the Full Blood Count
RDW-- Interpreting the Full Blood Count The most important components of a Full Blood Count report are, of course, the Haemoglobin, the White Cell Count and Differential and the Platelet Count. However,
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationAcute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma
Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively
More informationCML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationARTICLE IN PRESS Leukemia Research xxx (2010) xxx xxx
Leukemia Research xxx (2010) xxx xxx Contents lists available at ScienceDirect Leukemia Research journal homepage: www.elsevier.com/locate/leukres Clinical management of myelodysplastic syndromes: update
More informationRole of Stem Cell Transplantation in Patients With MDS. Anastasios Raptis MD, Ph.D.
Role of Stem Cell Transplantation in Patients With MDS Anastasios Raptis MD, Ph.D. Disclosures Millennium Celgene MDS: Biology Heterogeneous group of clonal acquired disorders Ineffective hematopoiesis
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationCorporate Medical Policy Genetic Testing for Fanconi Anemia
Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2016 3/2017 3/2016 Description
More informationFLOW CYTOMETRY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES
B. KÁRAI, E. SZÁNTHÓ, J. KAPPELMAYER, Z. HEVESSY FLOW CYTOMETRY IN THE DIAGNOSIS OF In this issue: FLOW CYTOMETRY IN THE CLINICAL LABORATORY The Journal of the International Federation of Clinical Chemistry
More informationNATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationHematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia
John L. Kennedy, M.D. UIC College of Medicine Associate Professor of Clinical Pathology M2 Pathology Course Lead Pathologist, VA Chicago Health Care System Lecture #43 Phone: (312) 569-6690 Thursday, November
More informationWhy discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
More informationimmunologic-- immunophenotypes are found by monoclonal antibodies - B-progenitor cells T-progenitor cells, mature B cells
Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Childhood ALL was the first form of cancer shown to be curable with chemotherapy and irradiation. Lymphoid leukemias
More informationHaematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation
Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Dr Ros Ganderton, Ms Kate Parratt, Dr Debbie Richardson, Dr Kim Orchard and Dr Liz Hodges Departments of Molecular Pathology
More informationSummary of the risk management plan (RMP) for Accofil (filgrastim)
EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure
More informationAnswering your questions on Chronic Myeloid Leukaemia (CML)
Answering your questions on Chronic Myeloid Leukaemia (CML) Your guide to understanding CML and Glivec (imatinib) treatment The information in this booklet is designed to help you understand chronic myeloid
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationPT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank
Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife
More informationAdult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
More informationAPPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML
More informationOther treatments for chronic myeloid leukaemia
Other treatments for chronic myeloid leukaemia This information is an extract from the booklet Understanding chronic myeloid leukaemia. You may find the full booklet helpful. We can send you a copy free
More informationRelative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani
Relative Risk (Sokal & Hasford): Relationship with Treatment Results Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Disease risk
More informationWhat is acute myeloblastic leukaemia?
Acute Myeloblastic Leukaemia What is acute myeloblastic leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationMultiple Myeloma Patient s Booklet
1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationTreating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationBiometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren
Biometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren Dipl.-Math. C. Sauerland (sauerla@uni-muenster.de) Dipl.-Biomath. S. Amler
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationP R E S S K I T 2013 TABLE OF CONTENTS. About the European Group for Blood and Marrow Transplantation
TABLE OF CONTENTS About the European Group for Blood and Marrow Transplantation Haematopoietic Stem Cell Transplantation (HSCT): Key facts & figures EBMT Data - A foundation for cutting-edge research Clinical
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationinformation for payers and referrers
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in
More informationGeneral Practice Referral Guidelines Haematology Department Southend University Hospital NHS Foundation Trust March 2014
General Practice Referral Guidelines Haematology Department Southend University Hospital NHS Foundation Trust March 2014 Dear Colleague The attached protocols have been designed with the aim of streamlining
More informationClinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. April 2013. Reference: NHSCB/B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation First published:
More informationInformation Pathway. Myeloma tests and investigations. Paraprotein measurement
Information Pathway Myeloma UK Broughton House 31 Dunedin Street Edinburgh EH7 4JG Tel: + 44 (0) 131 557 3332 Fax: + 44 (0) 131 557 9785 Myeloma Infoline 0800 980 3332 www.myeloma.org.uk Charity No. SC
More informationHematology Morphology Critique
Survey Slide: History: 60-year-old female presenting with pneumonia Further Laboratory Data: Hgb : 90 g/l RBC : 2.92 10 12 /L Hct : 0.25 L/L MCV : 87 fl MCH : 30.8 pg MCHC : 355 g/l RDW : 17.7 % WBC :
More informationCord blood Banking Transplant List for One USA Bank - StemCyte www.stemcyte.com/cordblood-banking-transplant-list
Cells4Life is the oldest and largest cord blood storage company in the UK. We are governed by some of the world's most stringent medical laws, and are currently the only stem cell storage company in the
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More information